Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 18/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.68 |
| ▸ | TNF | P01375 | 1/20 | 0.68 |
| ▸ | IL1B | P01584 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19953931 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29922428 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30241720 | 0.91 | DDB1 (0.83) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL17884399 | 0.88 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20437026 | 0.88 | DDB1 (0.78) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25876218 | 0.88 | DDB1 (0.78) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3655358 | 0.87 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26192246 | 0.87 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26192816 | 0.87 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3657756 | 0.85 | DDB1 (0.74) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-2991976-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2,6-DIONE | Celgene Corporation (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9266858-B2 | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione | CELGENE CORPORATION (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160009685-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2015160845-A2 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150274694-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2015-10-01 | — | — | US | disclosed |
| US-9067912-B2 | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,8-dione | CELGENE CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| WO-2014179416-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140330016-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330016-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | AZI2, DHPS, PKD2 | DDB1 3918/4885CRBN 1775/4885IKZF3 1900/4885 |
| US-20150274694-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | AZI2, DHPS, PKD2 | DDB1 3918/4885CRBN 1775/4885IKZF3 1900/4885 |
| US-20160058872-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | DDB1 360/4885CRBN 1/4885IKZF3 248/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | DDB1 433/4885CRBN 3/4885IKZF3 3470/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | DDB1 594/4885CRBN 5/4885IKZF3 719/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | DDB1 10/4885CRBN 158/4885IKZF3 329/4885 |
| US-20150291562-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | DDB1 360/4885CRBN 1/4885IKZF3 248/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | DDB1 987/4885CRBN 179/4885IKZF3 1442/4885 |
| US-20160009685-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | AZI2, DHPS, PKD2 | DDB1 3918/4885CRBN 1775/4885IKZF3 1900/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | DDB1 706/4885CRBN 74/4885IKZF3 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.